BR112023006328A2 - Tratamento de exacerbações no lúpus - Google Patents

Tratamento de exacerbações no lúpus

Info

Publication number
BR112023006328A2
BR112023006328A2 BR112023006328A BR112023006328A BR112023006328A2 BR 112023006328 A2 BR112023006328 A2 BR 112023006328A2 BR 112023006328 A BR112023006328 A BR 112023006328A BR 112023006328 A BR112023006328 A BR 112023006328A BR 112023006328 A2 BR112023006328 A2 BR 112023006328A2
Authority
BR
Brazil
Prior art keywords
treatment
exacerbations
lupus
sle
relates
Prior art date
Application number
BR112023006328A
Other languages
English (en)
Portuguese (pt)
Inventor
Kalyani Rubana
Abreu Gabriel
Tummala Rajendra
Furie Richard
Morand Eric
Askanase Anca
Vital Ed
Kalunian Kenneth
Lindholm Catharina
Maho Emmanuelle
Kleoudis Christi
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023006328A2 publication Critical patent/BR112023006328A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Glass Compositions (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023006328A 2020-10-08 2021-10-07 Tratamento de exacerbações no lúpus BR112023006328A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089355P 2020-10-08 2020-10-08
US202163178748P 2021-04-23 2021-04-23
PCT/EP2021/077702 WO2022074123A1 (en) 2020-10-08 2021-10-07 Treatment of flares in lupus

Publications (1)

Publication Number Publication Date
BR112023006328A2 true BR112023006328A2 (pt) 2023-05-09

Family

ID=78269610

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023006328A BR112023006328A2 (pt) 2020-10-08 2021-10-07 Tratamento de exacerbações no lúpus

Country Status (11)

Country Link
US (1) US20240026015A1 (https=)
EP (1) EP4225791A1 (https=)
JP (1) JP2023546361A (https=)
KR (1) KR20230082659A (https=)
CN (1) CN116406296A (https=)
AU (1) AU2021356122B2 (https=)
BR (1) BR112023006328A2 (https=)
CA (1) CA3197055A1 (https=)
IL (1) IL301759A (https=)
TW (1) TW202237647A (https=)
WO (1) WO2022074123A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3216390A1 (en) * 2021-04-23 2022-10-27 Astrazeneca Ab Treatment of cutaneous lupus erythematous
CN120392997A (zh) * 2021-04-23 2025-08-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
IL319505A (en) 2022-09-14 2025-05-01 Viatris Asia Pacific Pte Ltd S1P 1 receptor modulators for use in the treatment of diseases mediated by type 1 interferon
EP4545090A1 (en) * 2023-10-27 2025-04-30 Universität Leipzig Interferon-a receptor immune modulator for use as a medicament

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662381B2 (en) 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
CN101678100A (zh) * 2006-12-06 2010-03-24 米迪缪尼有限公司 治疗系统性红斑狼疮的方法
KR20160070165A (ko) 2008-02-08 2016-06-17 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
EP4494712A3 (en) * 2019-11-11 2025-03-26 Astrazeneca AB Type i interferon inhibition in systemic lupus erythematosus
EP4157873A2 (en) * 2020-05-29 2023-04-05 Astrazeneca AB Treatment of cardiometabolic disease with inhibitors of type i interferon signalling

Also Published As

Publication number Publication date
JP2023546361A (ja) 2023-11-02
WO2022074123A1 (en) 2022-04-14
AU2021356122B2 (en) 2026-02-05
AU2021356122A1 (en) 2023-06-08
EP4225791A1 (en) 2023-08-16
KR20230082659A (ko) 2023-06-08
US20240026015A1 (en) 2024-01-25
CA3197055A1 (en) 2022-04-14
CN116406296A (zh) 2023-07-07
TW202237647A (zh) 2022-10-01
IL301759A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112023006328A2 (pt) Tratamento de exacerbações no lúpus
IL310291A (en) Compositions and methods for inhibition of ras
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
IL280099A (en) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
MX2021009886A (es) Enzimas con dominios ruvc.
BR112018069533A2 (pt) tratamento de condições alérgicas oculares com ciclodextrinas
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
JOP20200132A1 (ar) صيغة مجففة بالتبريد من جسم مضاد أحادي النسيلة ضد ترانس ثيرتين
BR112018069220A2 (pt) uso de polipeptídeo que tem atividade de dnase para tratamento de tecidos
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
DOP2019000215A (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usándolo
UY38333A (es) Inhibidores de transglutaminasa 2 (tg2)
UY36357A (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa))
CL2018000108A1 (es) Moléculas de anticuerpo que se unen a cd22
HUE069592T2 (hu) Eljárások nanocellulóz diszperziók javítására elasztomer vegyületekben és az elasztomer vegyületekben diszpergált nanocellulózt tartalmazó készítmények
BR112024001180A2 (pt) Composições e métodos para tratamento do melanoma
MX2020002777A (es) Metodos y composiciones para tratamiento de epidermolisis ampollosa.
BR112019003601A2 (pt) anticorpos multiespecíficos que facilitam pareamento
BR112021026564A2 (pt) Método para estabilizar o ph de uma composição aquosa compreendendo um fármaco
EP4426263A4 (en) METHODS AND COMPOSITIONS FOR COSMETIC APPLICATIONS
MX2020009147A (es) Moduladores de la expresion de irf4.
EP4199750A4 (en) COMPOSITIONS AND METHODS FOR TREATING OBESITY
IL311867A (en) Trem compositions and methods of use
CL2020000397A1 (es) Formulaciones de anticuerpos inhibitorio para masp-2 de baja viscosidad altamente concentradas, kits, y métodos de tratamiento de sujetos que sufren de síndrome hemolítico atípico.
EP3993796C0 (en) COMBINATION FOR THE TREATMENT OF INFECTIONS CAUSED BY MYCOPLASMA GENITALIUM